References
- Loveday C. International perspectives on antiretroviral resistance: nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001; 26\(Suppl 1): S10–24. Review.
- Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001; 6(Suppl 3): 25–44.
- Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and Bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 1998; 42: 1484–7.
- Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 2002; 46: 1067–72.
- Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16: 1227–35.
- Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4: 87–94.
- Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM. Adefovir and tenofovir susceptibilities of HIV-1 after 24 and 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96–408. J Acquir Immune Defic Syndr 2001; 27: 450–8.
- Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001; 20: 1025–8.
- Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington J. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. The J Inf Dis 1999; 179: 92–100.
- Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257–63.
- Pozniak AL, Plettenberg A, Rozenbaum W, Sonnerborg A, Molina JM, Gatell J, et al. Tenofovir DF: a 48-week final analysis from a phase III randomized, double-blind, placebo controlled study in antiretroviral experienced patients (Study 907). XIV International AIDS Conference Barcelona, July 7–12, 2002. (Oral Number 1266).
- Nielsen SD, Jeppesen DL, Kolte L, Clark DR, Sorensen TU, Dreves AM, et al. Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood 2001; 98: 398–404.
- Stanford HIV Reverse Transcriptase and Protease Sequence Database. http://hivdb.stanford.edu/
- Los Alamos HIV database. http://hiv-web.lanl.gov/content/hiv-db/ SUBTYPE_REF/align.html.